neostigmine has been researched along with Acute Necrotizing Pancreatitis in 1 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schneider, L | 1 |
| Jabrailova, B | 1 |
| Soliman, H | 1 |
| Hofer, S | 1 |
| Strobel, O | 1 |
| Hackert, T | 1 |
| Büchler, MW | 1 |
| Werner, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Curative Effect and Security of Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension[NCT02543658] | Phase 2 | 80 participants (Actual) | Interventional | 2015-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Days in hospital within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | days (Median) |
|---|---|
| Neostigmine | 20 |
| Conservative Treatment | 19 |
Days in ICU within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | days (Median) |
|---|---|
| Neostigmine | 12 |
| Conservative Treatment | 12 |
Death during from randomization to 90 days after onset. (NCT02543658)
Timeframe: From randomization to 90 days after onset.
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 10 |
| Conservative Treatment | 11 |
Medical expenses within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | thousand(RMB) (Median) |
|---|---|
| Neostigmine | 95.3 |
| Conservative Treatment | 102.3 |
Abdominal compartment syndrome is defined as a sustained IAP>20 mmHg (with or without an APP<60 mmHg) that is associated with new organ dysfunction/failure (NCT02543658)
Timeframe: From randomization to discharge or death, assessed up to 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 2 |
| Conservative Treatment | 4 |
Incidence of organ failure from randomization to discharge or death, assessed up to 3 months (NCT02543658)
Timeframe: From randomization to discharge or death, assessed up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 12 |
| Conservative Treatment | 16 |
Due to that neostigmine has an inhibitory effect on the cardiovascular system, new-onset cardiovascular failure after grouping is considered as a possible adverse event related to neostigmine.Cardiovascular failure was defined as circulatory systolic blood pressure <90 mm Hg, despite adequate fluid resuscitation, or need for inotropic catecholamine support (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 8 |
| Conservative Treatment | 4 |
IAP rebound ≥ 5mmHg or increase ≥ 20mmHg within 1-7 days after grouping (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 4 |
| Conservative Treatment | 8 |
From date of randomization to enteral nutrition, assessed up to 30 days (NCT02543658)
Timeframe: Start time of enteral nutrition after randomization, assessed up to 30 days
| Intervention | days (Median) |
|---|---|
| Neostigmine | 3 |
| Conservative Treatment | 4 |
Monitor the intra-abdominal pressure within 1 to 7 days after randomization, and calculate the percent change compared with that before randomization (NCT02543658)
Timeframe: From randomization to 7 days after treatment,Measured IAP every 6 hours
| Intervention | percent change of IAP (Median) | |
|---|---|---|
| percent change of IAP at 24 hours | percent change of IAP at 7 days | |
| Conservative Treatment | -5.4 | -20.0 |
| Neostigmine | -18.7 | -27.2 |
After randomization, the change of stool volume (ML) was calculated every 24 hours.For example, the amount of stool volume decreased or increased in 24 hours after grouping compared to before grouping. (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | ml/day (Median) | |
|---|---|---|
| The change of stool volume at 24 hours | The change of stool volume at 7th day | |
| Conservative Treatment | 60 | 370 |
| Neostigmine | 870 | 1025 |
1 other study available for neostigmine and Acute Necrotizing Pancreatitis
| Article | Year |
|---|---|
Pharmacological cholinergic stimulation as a therapeutic tool in experimental necrotizing pancreatitis.
Topics: Animals; Cholinergic Agents; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Glycodeoxych | 2014 |